Delcath Lifts 2026 Revenue Guide to $108M-But the Real Test Is Center Growth vs. Profit Leakage

Delcath's guide-up moves the stock from narrative to execution

Delcath raised its 2026 revenue outlook to $104 million-$108 million, above the at least $100 million it set in May, after reporting $29.1 million in Q2 revenue. That matters because a higher outlook near prior market expectations leaves less room for a "maybe later" thesis. The question is no longer just whether HEPZATO has demand; it is whether management can actually pull that revenue through the expanding treatment network.

Why center growth now matters more

Delcath ended the quarter at 31 active treatment centers and remains on track to reach approximately 37 by year-end, with new patient starts and backup REMS-certified teams intended to support capacity. If those sites convert into treatments, the business gets closer to proving it is a scaling story rather than a niche drug story.

The bear case is still valid: center growth has to become durable monetization, not just more promised capacity. Revenue is moving up, but investors still need evidence that broader site access is translating into repeatable, profitable case volume.

HEPZATO still does most of the work

The raised guide is important, but only up to a point. The near-term question is whether Delcath can turn site additions into actual HEPZATO treatments. The latest quarter was still dominated by one product: HEPZATO KIT revenue was $27.1 million, while CHEMOSAT revenue in Europe increased to $2.0 million. That mix suggests the path to the top end of guidance depends less on nominal center count and more on whether those centers generate steady patient flow and repeat HEPZATO cases.

Higher margins help, but they do not settle the whole case

The positive signal is that the core economics improve with utilization. Delcath reported gross margin reached 90%, up from 86% a year earlier, while HEPZATO volume rose about 30% year over year. That supports the view that fixed costs are being spread over more cases and that additional HEPZATO procedures can be economically attractive.

Spending still offset the benefit

That said, the profit picture was not cleaner. Adjusted EBITDA was $7.6 million versus $9.8 million a year ago, even with the margin gain, because higher clinical and commercial spending contributed to a decline in non-GAAP adjusted EBITDA. In other words, Delcath is still spending ahead of the payoff to build the network, support trials, and broaden adoption.

The company also said enrollment has been slower than expected because of coordination and training requirements at treatment centers, which is a reminder that adding sites is not the same as instantly increasing throughput. On financing, cash and investments totaled $95.9 million at June 30, 2026, which gives management runway, but it does not eliminate the need for better conversion from capacity to revenue.

Analyst support is constructive, but short interest keeps the debate alive

The market view still leans constructive. Delcath has a Moderate Buy consensus, with an average price target is $22.17 and a range from $17.00 to $30.00. That spread captures the real debate: bulls see enough commercial momentum to justify a higher multiple if the center ramp keeps compounding, while bears still think the stock has to earn more of its upside.

Wall Street still believes in the scale story

Even the more cautious bullish stance points to that tension. Clear Street reaffirmed a positive stance while trimming its target to $27 from $29, which suggests analysts still see commercial upside but want to price in execution risk.

Shorts still have a meaningful voice

Short interest remains high enough to keep the stock unpredictable. One report showed 2.69M shares short, or 9.68% of the public float, with 7.7 days to cover. Another source listed 3.99M short shares, or 13.14% float, with 10.65 days to cover. That does not prove the story is wrong, but it does show that a meaningful part of the market still wants harder proof that revenue growth can outrun spending.

What to watch in the next few quarters

• Center-to-case conversion: More sites only matter if they show up in reported revenue and volume.
• HEPZATO concentration: If the mix stays heavily weighted to HEPZATO, execution risk remains concentrated in one commercial engine.
• Spend discipline: If operating costs keep rising faster than gross profit, the margin benefit from higher utilization will be harder to recognize in earnings.
• Training and enrollment: Slower center onboarding would weaken the case that 37 sites automatically mean better throughput.
• Sentiment signals: Another target cut despite stable guidance would signal weakening conviction, while falling short interest with rising price would suggest accumulation.